Phase 1b/2a multicenter RCT testing a single intradiscal injection of allogeneic STRO-3+ mesenchymal precursor cells (MPCs) with hyaluronic acid versus hyaluronic acid alone and saline in patients with chronic discogenic low back pain. The study enrolled 100 patients with moderate degenerative disc disease (modified Pfirrmann 3-6) who failed conservative care, with follow-up through 36 months. The primary question: is this approach safe, and does it reduce pain and disability compared to placebo?
Patients with chronic discogenic low back pain from moderate disc degeneration who have failed conservative care have limited minimally invasive options. Before this trial, intradiscal biologics lacked randomized human safety and efficacy data beyond 12 months.
This paper establishes that a single intradiscal MPC injection is biologically safe (no immune reactions, 0.5% discitis risk) and produces durable functional improvement through 36 months, with 47-50% of MPC patients achieving a clinically significant ODI reduction vs. 15% with saline.
When counseling a patient with moderate lumbar DDD (modified Pfirrmann 3-6) and discogenic pain who has failed 3+ months of conservative care, recognize that MPC injection is a Phase 2-level option with meaningful functional benefit — but frame expectations around pain and disability scores, not disc appearance on MRI.
Response is heterogeneous: roughly half of treated patients achieve clinically meaningful improvement while others do not respond. The authors attribute this partly to inadequate disc-level selection when discography was not mandated. A lesson for future trial design and patient selection.
Phase 1b/2a multicenter RCT testing a single intradiscal injection of allogeneic STRO-3+ mesenchymal precursor cells (MPCs) with hyaluronic acid versus hyaluronic acid alone and saline in patients with chronic discogenic low back pain. The study enrolled 100 patients with moderate degenerative disc disease (modified Pfirrmann 3-6) who failed conservative care, with follow-up through 36 months. The primary question: is this approach safe, and does it reduce pain and disability compared to placebo?
Patients with chronic discogenic low back pain from moderate disc degeneration who have failed conservative care have limited minimally invasive options. Before this trial, intradiscal biologics lacked randomized human safety and efficacy data beyond 12 months.
This paper establishes that a single intradiscal MPC injection is biologically safe (no immune reactions, 0.5% discitis risk) and produces durable functional improvement through 36 months, with 47-50% of MPC patients achieving a clinically significant ODI reduction vs. 15% with saline.
When counseling a patient with moderate lumbar DDD (modified Pfirrmann 3-6) and discogenic pain who has failed 3+ months of conservative care, recognize that MPC injection is a Phase 2-level option with meaningful functional benefit — but frame expectations around pain and disability scores, not disc appearance on MRI.
Response is heterogeneous: roughly half of treated patients achieve clinically meaningful improvement while others do not respond. The authors attribute this partly to inadequate disc-level selection when discography was not mandated. A lesson for future trial design and patient selection.